Polaprezinc ( DrugBank: Polaprezinc )


2 diseases
IDDisease name (Link within this page)Number of trials
96Crohn disease1
97Ulcerative colitis1

96. Crohn disease


Clinical trials : 2,400 Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000005970
2011/07/0113/07/2011Investigation on the remission maintaining effect of Polaprezinc in patients with Crohn's disease in remission phase. Patients with Crohn's disease in remission phasePolaprezinc administration group: patients has Polaprezinc 150mg/day for xxx months with Crohn's disease maintenance therapy.
Polaprezinc non administration group: patients treated with Crohn's disease maintenance therapy only.
Kawasaki Medical SchoolNULLRecruiting20years-oldNot applicableMale and Female100Not selectedJapan

97. Ulcerative colitis


Clinical trials : 2,527 Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000008967
2009/01/0124/09/2012Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis Ulcerative ColitisPolaprezinc group: Polaprezinc enema contained 150 mg of Polaprezinc suspension in tap water (total volume 100 mL) daily for one week

Placebo group: 100 mL tap water enema daily for one week
The Jikei University School of MedicineDivision of Gastroenterology and HepatologyNULLComplete: follow-up complete18years-oldNot applicableMale and Female30Not applicableJapan